What is the Origin of ASPREE Trial?

This extensive, international collaborative trial was initiated in 2010, involving participants aged 70 and older from both the United States and Australia. The study was designed to address the clinical uncertainty surrounding the routine use of aspirin for primary prevention in individuals without pre-existing cardiovascular disease.

What is the Mechanism of ASPREE Trial?

The study mechanism involved randomly assigning participants to receive either a daily dose of 100 mg of low-dose aspirin or a placebo over an average follow-up period of nearly five years. The key finding was that aspirin did not significantly extend disability-free longevity and, importantly, was associated with a statistically significant increase in the risk of major hemorrhage, particularly gastrointestinal bleeding.

ASPREE Trial ∞ Area

ASPREE Trial

Meaning

The ASPirin in Reducing Events in the Elderly (ASPREE) Trial was a landmark, large-scale, randomized, double-blind, placebo-controlled clinical study focused on determining the benefits and risks of daily low-dose aspirin in healthy older adults. The trial sought to answer whether aspirin could prolong healthy, independent living, defined as life free of dementia or persistent physical disability. It provided definitive evidence regarding primary prevention in the aging population.